AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28374661 — intervention group
Group type: COMPARATOR
Intervention: Conventional psychoeducation group (CPEG)
Number of subjects: 342
Study 28374661 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 342
Study 26503964 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone
Number of subjects: 56
Study 26503964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 24413638 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon β‐1a, 44 μg sc three times weekly or once weekly, for 24 months or until diagnosis of clinically definite multiple sclerosis (CDMS)
Number of subjects: 0
Study 24413638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22520631 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein levels
Number of subjects: 220
Study 22520631 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-factor modified prognostic model based on the TAX327 trial
Number of subjects: 220
Study 22520631 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein levels + TAX327 model risk estimates
Number of subjects: 220
Study 20061231 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management intervention
Number of subjects: 0
Study 20061231 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive case management programs
Number of subjects: 0
Study 20061231 — intervention group
Group type: COMPARATOR
Intervention: Hypothetical effects of case management
Number of subjects: 0
Study 17588396 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (15 mg/kg)
Number of subjects: 80
Study 17588396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 15179653 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee orthosis (KO)
Number of subjects: 18
Study 15179653 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle-foot orthosis (AFO)
Number of subjects: 18
Study 15179653 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee-ankle-foot orthosis (KAFO)
Number of subjects: 18
Study 15179653 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 18
Study 11454380 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg gemfibrozil daily for 6 weeks
Number of subjects: 22
Study 11454380 — intervention group
Group type: COMPARATOR
Intervention: 200 mg fenofibrate daily for 6 weeks
Number of subjects: 22
Study 9728307 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma AP locking nail (GAPN)
Number of subjects: 60
Study 9728307 — intervention group
Group type: COMPARATOR
Intervention: Compression hip screw (CHS)
Number of subjects: 60
Study 8700804 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0
Study 8700804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2808867 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with 20 micrograms epinephrine
Number of subjects: 12
Study 2808867 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with 80 micrograms epinephrine
Number of subjects: 12
Study 2808867 — intervention group
Group type: COMPARATOR
Intervention: Plain lidocaine solution
Number of subjects: 12
Study 1208040 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione‐bicarbonate‐Ringer's (GBR) solution
Number of subjects: 0
Study 1208040 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 0
Study 30607545 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant, palonosetron, and dexamethasone
Number of subjects: 108
Study 30607545 — intervention group
Group type: COMPARATOR
Intervention: Control group (palonosetron and dexamethasone)
Number of subjects: 108
Study 30607545 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant
Number of subjects: 108
Study 29212812 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 14837
Study 29212812 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 14837
Study 29212812 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 14837
Study 26130623 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ambroxol (40 mg/kg/day, in four divided doses)
Number of subjects: 66
Study 26130623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 26130623 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol
Number of subjects: 66
Study 23261355 — intervention group
Group type: EXPERIMENTAL
Intervention: p16-positive women
Number of subjects: 1042
Study 23261355 — intervention group
Group type: COMPARATOR
Intervention: p16-negative women
Number of subjects: 1042
Study 23261355 — intervention group
Group type: EXPERIMENTAL
Intervention: p16 testing
Number of subjects: 1042
Study 21712501 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored behavior change program (web-based and individual coaching)
Number of subjects: 314
Study 21712501 — intervention group
Group type: COMPARATOR
Intervention: No/low intervention dose
Number of subjects: 314
Study 21712501 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium intervention dose
Number of subjects: 314
Study 21712501 — intervention group
Group type: EXPERIMENTAL
Intervention: High intervention dose
Number of subjects: 314
Study 18618371 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg ramosetron hydrochloride once daily for 12 weeks
Number of subjects: 539
Study 18618371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 539
Study 16841626 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (40-120 mg/day)
Number of subjects: 896
Study 16841626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 896
Study 16841626 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 896
Study 12586006 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotope ratio mass spectrometer (IRMS)
Number of subjects: 41
Study 12586006 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondispersive isotope‐selective infrared spectrometer (NDIRS)
Number of subjects: 41
Study 10671629 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenate-supplemented formula (28 microg Se/8 oz)
Number of subjects: 79
Study 10671629 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenite-supplemented formula (28 microg Se/8 oz)
Number of subjects: 79
Study 10671629 — intervention group
Group type: COMPARATOR
Intervention: Non-fortified formula (7 microg Se/8 oz)
Number of subjects: 79
Study 9068934 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 12
Study 9068934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8103648 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia
Number of subjects: 18
Study 8103648 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with thiopental (2‐4 mg/kg) and low fentanyl dose (5 micrograms/kg)
Number of subjects: 18
Study 8103648 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with thiopental (2‐4 mg/kg) and high fentanyl dose (30 micrograms/kg)
Number of subjects: 18
Study 8103648 — intervention group
Group type: COMPARATOR
Intervention: Light general anesthetic
Number of subjects: 18
Study 8103648 — intervention group
Group type: COMPARATOR
Intervention: Deeper anesthetic
Number of subjects: 18
Study 8103648 — intervention group
Group type: COMPARATOR
Intervention: Atrioventricular conduction (PQ-time)
Number of subjects: 18
Study 3785608 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracranial-intracranial bypass surgery
Number of subjects: 0
Study 3785608 — intervention group
Group type: COMPARATOR
Intervention: Best available medical therapy
Number of subjects: 0
Study 3785608 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 29910611 — intervention group
Group type: EXPERIMENTAL
Intervention: tiotropium/olodaterol
Number of subjects: 3041
Study 29910611 — intervention group
Group type: COMPARATOR
Intervention: tiotropium
Number of subjects: 3041
Study 29910611 — intervention group
Group type: COMPARATOR
Intervention: olodaterol
Number of subjects: 3041
Study 27580428 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial valves (EBVs) plus standard of care (SoC)
Number of subjects: 93
Study 27580428 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC) alone
Number of subjects: 93
Study 27580428 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial valves (EBVs)
Number of subjects: 93
Study 24811183 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional hemodialysis (HD) sessions
Number of subjects: 10
Study 24811183 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis with blood volume tracking (HD-BVT)
Number of subjects: 10
Study 22494879 — intervention group
Group type: COMPARATOR
Intervention: Alcoholic beverage
Number of subjects: 96
Study 22494879 — intervention group
Group type: COMPARATOR
Intervention: Nicotinized cigarette
Number of subjects: 96
Study 22494879 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine and alcohol co-administration
Number of subjects: 96
Study 20356567 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination in HIV uninfected individuals
Number of subjects: 27
Study 20356567 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination in HIV infected individuals
Number of subjects: 27
Study 20356567 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccination
Number of subjects: 27
Study 17681713 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex ultrasound (DUS) surveillance after carotid stenting and angioplasty (CAS)
Number of subjects: 111
Study 17681713 — intervention group
Group type: EXPERIMENTAL
Intervention: DUS surveillance
Number of subjects: 111
Study 17681713 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular or surgical repair for high-grade stenosis
Number of subjects: 111
Study 17681713 — intervention group
Group type: EXPERIMENTAL
Intervention: DUS surveillance algorithm
Number of subjects: 111
Study 16234451 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure topical anaesthesia
Number of subjects: 18
Study 16234451 — intervention group
Group type: COMPARATOR
Intervention: Injection anaesthesia
Number of subjects: 18
Study 12167550 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (3 mg)
Number of subjects: 36
Study 12167550 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (0.75 mg)
Number of subjects: 36
Study 12167550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 12167550 — intervention group
Group type: EXPERIMENTAL
Intervention: Methamphetamine (20 mg)
Number of subjects: 36
Study 12167550 — intervention group
Group type: COMPARATOR
Intervention: Placebo (with methamphetamine)
Number of subjects: 36
Study 10459902 — intervention group
Group type: EXPERIMENTAL
Intervention: Cationic lipid-mediated CFTR gene transfer (active treatment)
Number of subjects: 16
Study 10459902 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lipid alone)
Number of subjects: 16
Study 8582818 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty or bypass grafting procedures
Number of subjects: 0
Study 8582818 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillators and heart transplantations
Number of subjects: 0
Study 8582818 — intervention group
Group type: EXPERIMENTAL
Intervention: General health outcomes
Number of subjects: 0
Study 8582818 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral for diagnostic and therapeutic procedures
Number of subjects: 0
Study 8582818 — intervention group
Group type: EXPERIMENTAL
Intervention: Research efforts for equitable health care
Number of subjects: 0
Study 2693373 — intervention group
Group type: EXPERIMENTAL
Intervention: Broncho-Vaxom
Number of subjects: 284
Study 2693373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study 31759193 — intervention group
Group type: EXPERIMENTAL
Intervention: PQ912 treatment (glutaminylcyclase inhibitor)
Number of subjects: 103
Study 31759193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 30098272 — intervention group
Group type: EXPERIMENTAL
Intervention: viable cryopreserved placental membrane (vCPM)
Number of subjects: 62
Study 30098272 — intervention group
Group type: COMPARATOR
Intervention: human fibroblast-derived dermal substitute (hFDS)
Number of subjects: 62
Study 28272673 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure™
Number of subjects: 18
Study 28272673 — intervention group
Group type: EXPERIMENTAL
Intervention: PlasmaKinetics™
Number of subjects: 18
Study 28272673 — intervention group
Group type: COMPARATOR
Intervention: Classic bipolar energy modality
Number of subjects: 18
Study 28272673 — intervention group
Group type: EXPERIMENTAL
Intervention: EnSeal®
Number of subjects: 18
Study 25795059 — intervention group
Group type: EXPERIMENTAL
Intervention: Phaco-canaloplasty (PC)
Number of subjects: 59
Study 25795059 — intervention group
Group type: COMPARATOR
Intervention: Phaco-non-penetrating deep sclerectomy (PDS)
Number of subjects: 59
Study 24009318 — intervention group
Group type: EXPERIMENTAL
Intervention: Wafer group (n=45) biting on a soft acrylic wafer during debond
Number of subjects: 90
Study 24009318 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=45)
Number of subjects: 90
Study 24009318 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study 20974053 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery intervention
Number of subjects: 20
Study 20974053 — intervention group
Group type: COMPARATOR
Intervention: Placebo control intervention (listening to audio book segments)
Number of subjects: 20
Study 19784511 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 L.min‐1 of oxygen (Group O)
Number of subjects: 94
Study 19784511 — intervention group
Group type: COMPARATOR
Intervention: Medical air (Group S)
Number of subjects: 94
Study 17035223 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-learning computer module (SLCM) instruction
Number of subjects: 52
Study 17035223 — intervention group
Group type: COMPARATOR
Intervention: Traditional instruction
Number of subjects: 52
Study 12784383 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-1 epitope
Number of subjects: 13
Study 12784383 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-3 epitope
Number of subjects: 13
Study 12784383 — intervention group
Group type: COMPARATOR
Intervention: Control peptides
Number of subjects: 13
Study 10642349 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (8 to 16 mg daily)
Number of subjects: 15
Study 10642349 — intervention group
Group type: COMPARATOR
Intervention: Control (15 control subjects)
Number of subjects: 15
Study 10642349 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 15
Study 9306438 — intervention group
Group type: EXPERIMENTAL
Intervention: Naugle exophthalmometer
Number of subjects: 135
Study 9306438 — intervention group
Group type: COMPARATOR
Intervention: Hertel exophthalmometer
Number of subjects: 135
Study 8350845 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure relief mattress (PRM)
Number of subjects: 128
Study 8350845 — intervention group
Group type: COMPARATOR
Intervention: Standard, firm mattress (Control)
Number of subjects: 128
Study 3520129 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltitol (50g)
Number of subjects: 50
Study 3520129 — intervention group
Group type: COMPARATOR
Intervention: Maltitol (10g 3 times daily for 5 days)
Number of subjects: 50
Study 3520129 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltitol
Number of subjects: 50
Study 31545373 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapies in single-arm trials
Number of subjects: 120
Study 31545373 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapies with observed rates 10 percentage points higher than upper targets
Number of subjects: 120
Study 31545373 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-arm combination trials
Number of subjects: 120
Study 28944500 — intervention group
Group type: EXPERIMENTAL
Intervention: Absurd events with parent laughter
Number of subjects: 113
Study 28944500 — intervention group
Group type: COMPARATOR
Intervention: Absurd events with neutral parent affect
Number of subjects: 113
Study 28944500 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinary events
Number of subjects: 113
Study 27368085 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma scripts
Number of subjects: 25
Study 27368085 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress scripts
Number of subjects: 25
Study 27368085 — intervention group
Group type: COMPARATOR
Intervention: Neutral scripts
Number of subjects: 25
Study 27368085 — intervention group
Group type: EXPERIMENTAL
Intervention: All scripts (trauma, stress, neutral)
Number of subjects: 25
Study 24996596 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported Care, a multimodal smoking cessation intervention
Number of subjects: 800
Study 24996596 — intervention group
Group type: COMPARATOR
Intervention: Normal Care, consisting of existing hospital care only
Number of subjects: 800
Study 22257614 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil SR treatment strategy
Number of subjects: 2317
Study 22257614 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol treatment strategy
Number of subjects: 2317
Study 22257614 — intervention group
Group type: COMPARATOR
Intervention: Both treatment strategies
Number of subjects: 2317
Study 20169490 — intervention group
Group type: EXPERIMENTAL
Intervention: Water suppression system (0.13, 0.06, 0.03, or 0.02 L/sec of water)
Number of subjects: 2000000
Study 20169490 — intervention group
Group type: EXPERIMENTAL
Intervention: Local exhaust ventilation (LEV) system (0.24, 0.13, or 0.12 m(3)/sec of dust laden air)
Number of subjects: 2000000
Study 20169490 — intervention group
Group type: COMPARATOR
Intervention: No control treatment
Number of subjects: 2000000
Study 18023335 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (2x9 microg lower dose; 6x9 microg higher dose)
Number of subjects: 26
Study 18023335 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (3x400 microg lower dose; 9x400 microg higher dose)
Number of subjects: 26
Study 18023335 — intervention group
Group type: COMPARATOR
Intervention: Formoterol and Salbutamol
Number of subjects: 26
Study 18023335 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 26
Study 16569189 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based implementation (EBI)
Number of subjects: 52
Study 16569189 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 52
Study 12757028 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozonated autohemotherapy with ozone concentration 50 microg/ml per gram of blood
Number of subjects: 12
Study 12757028 — intervention group
Group type: COMPARATOR
Intervention: Autohemotherapy with blood exposure to oxygen
Number of subjects: 12
Study 11134094 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/day micronized 17ss-estradiol
Number of subjects: 100
Study 11134094 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/day micronized 17ss-estradiol
Number of subjects: 100
Study 11134094 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/day micronized 17ss-estradiol
Number of subjects: 100
Study 11134094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 9079233 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril treatment
Number of subjects: 900
Study 9079233 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril/hydrochlorothiazide treatment
Number of subjects: 900
Study 9079233 — intervention group
Group type: COMPARATOR
Intervention: Intensified non-pharmacological treatment
Number of subjects: 900
Study 9079233 — intervention group
Group type: COMPARATOR
Intervention: Previous or adjusted medication
Number of subjects: 900
Study 8436163 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine
Number of subjects: 16
Study 8436163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3717956 — intervention group
Group type: COMPARATOR
Intervention: Regimen A (CDDP 75 mg/m2 and ADM 50 mg/m2 every 4 weeks)
Number of subjects: 85
Study 3717956 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B (CDDP 75 mg/m2, ADM 50 mg/m2, plus VCR 1.4 mg/m2 on day 1 and 0.7 mg/m2 on day 7 every 4 weeks)
Number of subjects: 85
Study 3717956 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders (both regimens)
Number of subjects: 85
Study 3717956 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-responders (both regimens)
Number of subjects: 85
Study 31773475 — intervention group
Group type: EXPERIMENTAL
Intervention: Total bilirubin levels measured at baseline
Number of subjects: 3824
Study 31773475 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically elevated total bilirubin level (rs6742078 variant)
Number of subjects: 3824
Study 30516797 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline plus enhanced medication management
Number of subjects: 223
Study 30516797 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy plus sertraline
Number of subjects: 223
Study 30516797 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy plus placebo
Number of subjects: 223
Study 27779776 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 10 mg as a bolus followed by 2.5 mg infusion over 2 hours
Number of subjects: 36
Study 27779776 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil doses (2.5 mg, 5 mg, 10 mg)
Number of subjects: 36
Study 27779776 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (Revatio®)
Number of subjects: 36
Study 25406308 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media exposure from Circulation (121 articles)
Number of subjects: 243
Study 25406308 — intervention group
Group type: COMPARATOR
Intervention: Control group (122 articles)
Number of subjects: 243
Study 23601186 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paricalcitol, 2 μg per day for the first year posttransplant
Number of subjects: 100
Study 23601186 — intervention group
Group type: COMPARATOR
Intervention: No additional therapy (Control)
Number of subjects: 100
Study 23601186 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paricalcitol, 2 μg per day
Number of subjects: 100